Bullpen.News From Edwin Dorsey
Get Daily Recap Feedback

Thursday, August 13

Thursday, August 13, 2026

Everything we published on this day.

54 stories — the front page that day →

Adobe Inc.

Adobe’s 11x P/E reflects AI disruption fears, but its creative standards, product bundling and Firefly monetisation support the case for…

ADBE $90B
Global Outperformers

Adobe Inc.

Adobe’s valuation fell from 70x earnings in 2020 to 11x as generative AI challenges its creative-software franchise; product standards,…

ADBE $90B
Global Outperformers 1 click

WillScot Q2'26: The Streak Is Over

WillScot Mobile Mini returned to revenue growth in Q2 2026, raised full-year targets and invested $114 million in fleet capacity for data…

WSC $3B
Monte Independent Investment Research
@KEDM_COM 1 click

KEDM.com on X

SEACOR Marine $SMHI has launched a strategic review, looking for value maximizing transactions – tough, clearly preferably a full sale. This comes after a ton of pressure from Pointillist (the largest shareholder), which argued SMHI’s market cap massively undervalues a fleet. Their thesis: the offshore cycle has fully recovered, but SMHI’s equity still trades at well below its $22/share broker appraised value. Seacor remains weighed down by high interest costs, G&A expenses, and subpar utilization, forcing asset sales to bolster liquidity. The premium PSV fleet alone should be worth ~$11/ share, with FSVs and Middle East liftboats pushing embedded value to $15/share+, vs. today’s price.
@KEDM_COM 2 clicks

KEDM.com on X

Uranium Royalty $UROY completed its (asset) deal with Sweetwater Royalties. This was quite the big deal for UR, not only in size ($1.9bn in EV and roughly $1.1bn in equity acquired, vs C$490m EV and C$600m market cap for UROY), but also because it will drastically reduce exposure to just one main commodity. The company recently listed on the Nasdaq and delisted from the TSX. In short, a transformative acquisition (trona is an interesting commodity) which should help the valuation. BB is not yet showing the correct financials, and coverage is picking up.
@ActAccordingly

PAA Research on X

Many. High level, the $AIRS quarter wasn't as good as hoped, but certainly not something that warranted the kind of response it received. Top of the funnel interest in lipo slowed in June/July. I have my own thesis on the potential impact of the world cup, given the shift in consumer interest in that procedure towards the latina community over the past 15-years. Only time will tell if that's right. Either way, the business is stable and now oriented for growth. Adding new procedures (eye bleph and alloclae) significantly expands $AIRS ability to serve the GLP-1 crowd. My expectation is we'll see the bank deal completed before they report 3Q26 and that could coincide with the announcement of site expansion in early 2027. The growth opportunity here remains monumental. $AIRS has massive inherent operating leverage to improved site level utilization. There was some fast money and retail involved here (clearly!), but this is about the company improving the marketing funnel in absolute lead generation and conversion, driving site level utilization, and expanding on a de novo basis. That's the recipe and obsessing about whether growth should have been 2-4% higher for 2Q26 in that context is irrelevant. This is a business that can be 3-5x the size and still have a runway for growth.
@eriksen_tim 2 clicks

Tim Eriksen on X

Is $EVC is a classic case of thesis drift for its investors? It was all about sequential hypergrowth (with a supposed SOTP margin of safety). Mgmt said Q3 will be below Q2. Now the thesis is about strong year over year growth. What happens in a few quarters when year over year growth is gone, or is low single digits? Is this really a seasonal business? For me it was a small position due to the nature of the situation. Q2 growth was lighter than I expected so I was selling after hours and have fully exited.
@BlueDuckCap 1 click

BDC on X

$XGN remains a top holding for us. Even after the big move higher post a beat and raise Q2, the shares trade for a material discount versus comps. The discount is silly. Especially when we consider that they are launching a new marker for Myositis. XGN tells us that Rheumatologists are BY FAR requesting a precise diagnostic for Myositis more than any other condition. The reason is because Myositis is treatable if caught early, but problematic if not. "this is the #1 asked for product amongst our rheumatologists clinical base... it's not even close to the #2 asked for offering" $XGN trades for 2x 2026 revenues. Comps go for 10x.